Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

P2, N=50, Not yet recruiting, Universiteit Antwerpen

We confirmed separate lots of the 9vHPV vaccine contained low copy numbers of L1 DNA, but found 9vHPV vaccine-generated antibody responses were not dependent on DNA sensing. This study has thus refined our understanding of potential mechanisms underlying the strong and long-lasting antibody responses to HPV vaccination.

P4, N=275, Recruiting, University of British Columbia | N=450 --> 275

P3, N=1099, Completed, Imperial College London | Active, not recruiting --> Completed

P3, N=536, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Aug 2025

P4, N=352, Active, not recruiting, Boston Medical Center | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Apr 2026

No significant differences were observed in anal dysplasia regression or anal microbiota composition over 12 months. Given the lack of short-term secondary benefit and persistence of HPV incidence, MSM with HIV require continued routine anal cancer screening.

P3, N=700, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Nov 2025 --> May 2026

P=N/A, N=2500, Not yet recruiting, Indiana University | Trial primary completion date: Feb 2028 --> Aug 2028

P1/2, N=50, Not yet recruiting, Ohio State University

P4, N=750, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Apr 2026 --> Dec 2026 | Recruiting --> Active, not recruiting

P4, N=150000, Active, not recruiting, Karolinska Institutet